Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-a...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601649/ |